Inogen Inc (INGN) Expected to Post Earnings of $0.52 Per Share
Wall Street analysts predict that Inogen Inc (NASDAQ:INGN) will post $0.52 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Inogen’s earnings, with estimates ranging from $0.48 to $0.58. Inogen posted earnings per share of $0.33 during the same quarter last year, which indicates a positive year over year growth rate of 57.6%. The business is expected to report its next earnings results on Tuesday, November 6th.
On average, analysts expect that Inogen will report full year earnings of $2.07 per share for the current financial year, with EPS estimates ranging from $2.01 to $2.12. For the next financial year, analysts expect that the company will report earnings of $2.17 per share, with EPS estimates ranging from $1.97 to $2.27. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Inogen.
Inogen (NASDAQ:INGN) last posted its earnings results on Tuesday, August 7th. The medical technology company reported $0.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.21. Inogen had a net margin of 10.39% and a return on equity of 16.51%. The company had revenue of $97.24 million for the quarter, compared to analyst estimates of $81.61 million.
Shares of INGN traded up $5.70 on Tuesday, reaching $258.66. The company’s stock had a trading volume of 232,400 shares, compared to its average volume of 193,425. Inogen has a twelve month low of $91.80 and a twelve month high of $287.79. The firm has a market capitalization of $5.44 billion, a PE ratio of 197.45, a P/E/G ratio of 5.03 and a beta of 1.22.
In other Inogen news, insider Matt Scribner sold 2,000 shares of the stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $281.23, for a total value of $562,460.00. Following the completion of the sale, the insider now owns 7,595 shares in the company, valued at approximately $2,135,941.85. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Byron Myers sold 24,953 shares of the stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $227.13, for a total transaction of $5,667,574.89. Following the completion of the sale, the executive vice president now owns 42,329 shares of the company’s stock, valued at approximately $9,614,185.77. The disclosure for this sale can be found here. Insiders sold a total of 106,308 shares of company stock worth $23,498,421 in the last 90 days. 5.29% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the business. Catalyst Capital Advisors LLC purchased a new stake in Inogen in the 2nd quarter valued at about $112,000. Advisors Preferred LLC purchased a new stake in Inogen in the 2nd quarter valued at about $176,000. SG Americas Securities LLC purchased a new stake in Inogen in the 1st quarter valued at about $178,000. Thompson Siegel & Walmsley LLC purchased a new stake in Inogen in the 2nd quarter valued at about $186,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new stake in Inogen in the 2nd quarter valued at about $216,000. Hedge funds and other institutional investors own 96.47% of the company’s stock.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also: What does RSI mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.